Efficacy
BOR
DISEASE
At the data cutoff date, eight patients were evaluable for efficacy and 1 patient was not evaluable for efficacy due to no measurable disease pre-infusion per IRC review. Per IRC assessment, the CRR was 100% (8/8; 95% CI 63.1–100) in the EAS (Fig. Response and survival outcomes (Efficacy analysis set). A patient who was excluded from the EAS due to no measurable disease at baseline per IRC achieved a BOR of PR with DOR 3.3 months, PFS 6.0 months and OS 12.0 + months. “ + ” denotes a censored observation. Kaplan–Meier curves of 